Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cann Group ( (AU:CAN) ) has issued an update.
Cann Group has entered the UK market with its first export of around 120 kilograms of own-grown medicinal cannabis flower from its Mildura facility, demonstrating its ability to meet strict international GMP and regulatory requirements. The company also secured German AMRadV licences via a commercial partner, clearing a key regulatory hurdle for exporting irradiated cannabis products and positioning it to expand into one of Europe’s largest medical cannabis markets later this year.
The broader sector received a boost as the Trump administration moved to reclassify FDA-approved and state-licensed medical marijuana as a less dangerous Schedule III drug, a shift expected to drive more research, clinical evidence and institutional investment in medicinal cannabis. Cann Group reported its strongest B2B quarter so far in FY2026, with revenue up 42% on the prior quarter to $2.32 million, cash outflows from operations down sharply, and management exploring strategic partnering options to support its next phase of growth.
More about Cann Group
Cann Group Limited is an Australian medicinal cannabis producer that cultivates and manufactures pharmaceutical-grade cannabis products at scale, including dried flower, from its Mildura facility. The company focuses on business-to-business supply and is pursuing international growth, targeting key regulated markets such as the United Kingdom and Germany under stringent GMP and regulatory standards.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.87M
Find detailed analytics on CAN stock on TipRanks’ Stock Analysis page.